Quantcast

Latest Ocera Therapeutics Inc. Stories

2010-12-15 07:00:00

SAN DIEGO, Dec. 15, 2010 /PRNewswire/ -- Ocera Therapeutics, Inc. announced today that it has completed two studies evaluating the safety and pharmacokinetics of OCR-002 (ornithine phenylacetate) which includes healthy volunteers and patients with liver cirrhosis. OCR-002 recently received Orphan Drug status and Fast Track designation by the United States Food and Drug Administration for the treatment of hyperammonemia (excessive ammonia levels) and resultant Hepatic encephalopathy....

2010-05-03 08:00:00

NEW ORLEANS, May 3 /PRNewswire/ -- Ocera Therapeutics, Inc. presented today an analysis of the prevalence of neurocognitive impairment in ambulatory cirrhotic patients at Digestive Disease Week (DDW), the annual meeting of the American Gastroenterological Association. The data, which came from the screening period of the ASTUTE Study demonstrated that 54% of the 301 cirrhotic patients screened had neurocognitive impairment. ASTUTE is an ongoing Phase 2b study evaluating the safety and...

2010-05-03 08:00:00

NEW ORLEANS, May 3 /PRNewswire/ -- Ocera Therapeutics, Inc. presented results yesterday from a Phase 2 proof-of-concept study of AST-120 (spherical carbon adsorbent) in the treatment of patients with non-constipating Irritable Bowel Syndrome (IBS) at DDW, the annual meeting of the American Gastroenterological Association. Data showed that subjects treated with AST-120 responded in a consistent manner with reduction in pain better than placebo at week four and at week eight, the primary...

2010-04-16 06:00:00

VIENNA, April 16 /PRNewswire/ -- Ocera Therapeutics, Inc. presented an analysis of the prevalence of neurocognitive impairment in ambulatory cirrhotic patients. The data came from the screening period of the ASTUTE Study, an ongoing Phase 2b study evaluating the safety and efficacy of AST-120 (spherical carbon adsorbent) in the treatment of mild hepatic encephalopathy (MHE). The poster was presented yesterday at the annual meeting of the European Association for the Study of Liver (EASL)...

2010-02-23 14:12:00

SAN DIEGO, Feb. 23 /PRNewswire/ -- Ocera Therapeutics, Inc. announced today that the ASTUTE Study (AST-120 Used to Treat Hepatic Encephalopathy) has completed enrollment for its Phase 2B study ahead of schedule, with data expected mid 2010. AST-120 adsorbs ammonia and other gut derived toxins that factor prominently in the underlying cause of mild hepatic encephalopathy (MHE), a neurocognitive disorder present in a majority of patients with cirrhosis of the liver. Because MHE leads to a...

2009-11-02 07:00:00

BOSTON, Nov. 2 /PRNewswire/ -- UCL Liver Failure Group presented data from two studies with OCR-002 (L-ornithine phenylacetate) that suggest the potential for this novel therapeutic agent to impact multiple aspects of liver disease and its complications. OCR-002 is licensed to Ocera Therapeutics, Inc. of San Diego, California. The data, presented at the 60th annual meeting of the American Association for the Study of Liver Diseases, is comprised of a set of studies evaluating the...

2009-11-02 07:00:00

BOSTON, Nov. 2 /PRNewswire/ -- Ocera Therapeutics, Inc. announced today that AST-120 (spherical carbon adsorbent) was shown to reduce the severity of pruritus (itching) in patients with chronic liver disease. The data were presented at the 60th Annual Meeting of the American Association for the Study of Liver Diseases in a presentation titled, "Oral AST-120 (Spherical Carbon Adsorbent) Improves Pruritus and Lowers Serum Bile Acids in Patients with Cirrhosis of Various Etiologies." These...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.